Wednesday, July 15, 2020 12:57:58 AM
So what
Imperial College London will conduct the trial to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia. Fostamatinib is Rigel's oral spleen tyrosine kinase (SYK) inhibitor. It's already approved for the treatment of an autoimmune disorder in the U.S. and Europe, which could help to speed the delivery of the drug to COVID-19 patients if it proves effective.
A person in a business suit is drawing an upwardly sloping line.RIGEL PHARMACEUTICALS' STOCK ROCKETED HIGHER ON TUESDAY. IMAGE SOURCE: GETTY IMAGES.
Researchers at Harvard and MIT recently led an effort to screen compounds that reduce a biomarker used to predict the development of lung injuries and respiratory distress in patients. Of the 3,713 compounds they studied, fostamatinib was the only FDA-approved compound that did so.
"Severe COVID-19 pneumonia can lead to acute respiratory distress syndrome, or ARDS, which can often be fatal," Rigel CEO Raul Rodriguez said in a press release. "Given encouraging data from pre-clinical models of fostamatinib, we believe there is potential for SYK inhibition to help treat the severity of the disease for these patients and to prevent ARDS."
Now what
Patients will randomly receive either fostamatinib, Novartis' (NYSE: NVS) chemotherapy ruxolitinib, or standard of care. The goal of the trial is to determine whether these treatments reduce the number of patients who progress from mild or moderate COVID-19 pneumonia to more severe cases.
Rigel and Novartis will provide support for this trial, and Rigel intends to eventually begin a trial of its own design. "We are pleased to be able to support the exciting work being done by our colleagues at Imperial College London," Rodriguez said. "Their efforts will be valuable as we explore fostamatinib in COVID-19 and pursue our plans for a Rigel-led study."
https://www.google.com/amp/s/www.fool.com/amp/investing/2020/07/14/why-rigel-pharmaceuticals-stock-skyrocketed-91-tod.aspx
Recent RIGL News
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/10/2024 08:30:00 PM
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma • PR Newswire (US) • 04/04/2024 12:05:00 PM
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer • PR Newswire (US) • 03/12/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:10:40 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:06:00 PM
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 03/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:16:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:15:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:15:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:14:43 AM
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update • PR Newswire (US) • 02/27/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:00:39 PM
- Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® • PR Newswire (US) • 02/22/2024 12:50:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:30:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:18:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:18:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:18:16 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 02:56:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:17:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:17:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:17:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:16:50 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 06:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:13 PM
- Rigel Pharmaceuticals Provides Business Update • PR Newswire (US) • 01/08/2024 01:05:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM